Free Trial

Ocular Therapeutix (OCUL) Competitors

Ocular Therapeutix logo
$9.36 -0.10 (-1.06%)
Closing price 07/3/2025 01:45 PM Eastern
Extended Trading
$9.62 +0.26 (+2.78%)
As of 07/3/2025 04:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OCUL vs. AXSM, AKRO, PCVX, ADMA, PTCT, RYTM, CYTK, KRYS, ZLAB, and ACAD

Should you be buying Ocular Therapeutix stock or one of its competitors? The main competitors of Ocular Therapeutix include Axsome Therapeutics (AXSM), Akero Therapeutics (AKRO), Vaxcyte (PCVX), ADMA Biologics (ADMA), PTC Therapeutics (PTCT), Rhythm Pharmaceuticals (RYTM), Cytokinetics (CYTK), Krystal Biotech (KRYS), Zai Lab (ZLAB), and ACADIA Pharmaceuticals (ACAD). These companies are all part of the "pharmaceutical products" industry.

Ocular Therapeutix vs. Its Competitors

Axsome Therapeutics (NASDAQ:AXSM) and Ocular Therapeutix (NASDAQ:OCUL) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are held by institutional investors. 22.3% of Axsome Therapeutics shares are held by company insiders. Comparatively, 2.3% of Ocular Therapeutix shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Axsome Therapeutics has a net margin of -64.39% compared to Ocular Therapeutix's net margin of -323.09%. Ocular Therapeutix's return on equity of -59.92% beat Axsome Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Axsome Therapeutics-64.39% -272.80% -36.69%
Ocular Therapeutix -323.09%-59.92%-41.98%

Axsome Therapeutics has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500. Comparatively, Ocular Therapeutix has a beta of 1.43, meaning that its share price is 43% more volatile than the S&P 500.

In the previous week, Axsome Therapeutics had 15 more articles in the media than Ocular Therapeutix. MarketBeat recorded 17 mentions for Axsome Therapeutics and 2 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 1.21 beat Axsome Therapeutics' score of 0.07 indicating that Ocular Therapeutix is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Axsome Therapeutics
4 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Ocular Therapeutix
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Ocular Therapeutix has lower revenue, but higher earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Axsome Therapeutics$385.69M13.45-$287.22M-$5.77-18.26
Ocular Therapeutix$63.72M23.40-$193.51M-$1.15-8.14

Axsome Therapeutics currently has a consensus target price of $172.33, suggesting a potential upside of 63.57%. Ocular Therapeutix has a consensus target price of $17.33, suggesting a potential upside of 85.19%. Given Ocular Therapeutix's higher possible upside, analysts plainly believe Ocular Therapeutix is more favorable than Axsome Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Axsome Therapeutics
0 Sell rating(s)
0 Hold rating(s)
15 Buy rating(s)
1 Strong Buy rating(s)
3.06
Ocular Therapeutix
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Axsome Therapeutics beats Ocular Therapeutix on 9 of the 17 factors compared between the two stocks.

Get Ocular Therapeutix News Delivered to You Automatically

Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OCUL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OCUL vs. The Competition

MetricOcular TherapeutixMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.53B$2.72B$5.56B$9.04B
Dividend YieldN/A1.78%5.24%4.01%
P/E Ratio-8.149.2227.6620.25
Price / Sales23.40668.89415.41118.18
Price / CashN/A158.5936.8958.07
Price / Book4.664.588.035.67
Net Income-$193.51M$31.34M$3.18B$249.21M
7 Day Performance1.52%3.25%2.93%3.27%
1 Month Performance10.64%7.08%3.75%5.55%
1 Year Performance40.33%0.17%35.20%21.08%

Ocular Therapeutix Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OCUL
Ocular Therapeutix
3.9657 of 5 stars
$9.36
-1.1%
$17.33
+85.2%
+39.9%$1.53B$63.72M-8.14230Gap Up
AXSM
Axsome Therapeutics
4.7445 of 5 stars
$101.65
+1.0%
$172.33
+69.5%
+31.3%$4.96B$385.69M-17.62380Trending News
Analyst Forecast
Analyst Revision
AKRO
Akero Therapeutics
3.4657 of 5 stars
$54.03
-0.3%
$82.50
+52.7%
+137.2%$4.32BN/A-27.7130Insider Trade
PCVX
Vaxcyte
1.7969 of 5 stars
$33.25
+1.2%
$136.50
+310.5%
-56.4%$4.24BN/A-8.33160News Coverage
ADMA
ADMA Biologics
4.2263 of 5 stars
$17.87
+0.7%
$27.67
+54.8%
+63.2%$4.24B$426.45M21.02530Positive News
PTCT
PTC Therapeutics
4.3213 of 5 stars
$49.60
-1.2%
$65.00
+31.0%
+57.3%$3.98B$806.78M7.621,410Analyst Revision
RYTM
Rhythm Pharmaceuticals
3.8158 of 5 stars
$62.13
+0.2%
$76.62
+23.3%
+61.2%$3.94B$130.13M-22.11140News Coverage
CYTK
Cytokinetics
3.9341 of 5 stars
$32.64
+0.6%
$70.92
+117.3%
-37.7%$3.87B$18.47M-6.17250
KRYS
Krystal Biotech
4.5851 of 5 stars
$137.92
+4.1%
$211.13
+53.1%
-19.5%$3.83B$290.52M33.15210News Coverage
Analyst Revision
High Trading Volume
ZLAB
Zai Lab
3.4348 of 5 stars
$36.01
+4.2%
$47.37
+31.5%
+111.6%$3.81B$398.99M-14.461,869News Coverage
Insider Trade
Analyst Revision
Gap Up
ACAD
ACADIA Pharmaceuticals
4.624 of 5 stars
$22.48
-1.0%
$27.64
+23.0%
+34.4%$3.80B$957.80M16.41510

Related Companies and Tools


This page (NASDAQ:OCUL) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners